Explore the vast range of titles available.

Chronic lymphocytic leukemia (CLL) is divided into unmutated (UM-CLL) and mutated (M-CLL) subtypes depending on somatic hypermutation (SHM) frequency in their immunoglobulin heavy chain V (IGHV) region. We previously demonstrated that CD27 bright memory B cells (MBCs) are germinal center (GC)-dependent with higher mutation rate, whereas CD27 dull MBCs accumulate fewer mutations and originate independently from the GC. We conducted a meta-transcriptomic analysis on bulk RNA data from 116 individuals combining four CLL cohorts and healthy B cell subsets (naïve, CD27 dull and CD27 bright MBCs) to decipher the transcriptional and mechanistic functions of CLL subtypes. CD27 bright MBCs showed more transcriptional similarity to M-CLL rather than UM-CLL. Functional enrichment analysis revealed that LPL , ZNF667 and ZNF667-AS1 are potential informative biomarkers for stratification of CLL subtypes. They are part of the mechanistic regulatory pathways of CLL pathology through cholesterol and Epithelial Mesenchymal Transition (EMT) regulation. We applied markers for the GC B-cell substages to map in silico the CLL cohorts to their potential GC B cell counterpart. UM-CLL represented transcriptional mimicry to an early intermediary GC substage whereas M-CLL mimicked later substages in the GC. This could potentially explain the IGHV mutational status of M-CLL as well as hypothesize that CLL subtypes could derive from a GC-dependent pathway.

Six new compounds, (7R,8S,8′R)-balanophorone (1), (7′S,8′R,8R)-yunnanensin A (2), (3S)-thunberginol C (3), (8R,8′R)-maninsigin B (4), (7S,8R)-4,7,8-dihydroxy-9,9-dimethyl-chroman (5), and 4-hydroxy-1-(4-hydroxy-3-methoxyphenyl)butan-1-one (6), along with eight known compounds (7–14), were isolated from the herbaceous stems of Ephedra intermedia Schrenket C. A. Meyer. Their structures were elucidated based on their spectroscopic (MS, NMR, IR, and UV) data, and their absolute configurations were determined by comparing their calculated and experimental electronic circular dichroic (ECD) spectra. Moreover, compounds 1 and 3–6 were evaluated for their ability to protect human pulmonary epithelial cells (BEAS-2B) from injury induced by lipopolysaccharide (LPS) in vitro. The results showed that compound 6 exhibited a significant protective effect against LPS-induced injury in BEAS-2B, and compound 5 exhibited a slightly protective effect at the concentration of 10 μM.

In total, this study provides insights into the multifaceted role of unswitched memory B cells during viral infection. Since many different types of B cells exist in homeostasis, arise in response to infection, or develop along with autoimmunity and strategies used in the field to identify subsets can be heterogeneous,Pernes et al.caution against using surface markers alone to profile B cell subsets. [...]this editor believes that development of technology that can link protein & gene expression with cellular function will ultimately provide the best advantage to shedding light on the complex nature of unswitched memory B cells in human health and disease. Conflict of interest The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

SARS-CoV-2 infection represents a global health problem that has affected millions of people. The fine host immune response and its association with the disease course have not yet been fully elucidated. Consequently, we analyze circulating B cell subsets and their possible relationship with COVID-19 features and severity. Using a multiparametric flow cytometric approach, we determined B cell subsets frequencies from 52 COVID-19 patients, grouped them by hierarchical cluster analysis, and correlated their values with clinical data. The frequency of CD19 B cells is increased in severe COVID-19 compared to mild cases. Specific subset frequencies such as transitional B cell subsets increase in mild/moderate cases but decrease with the severity of the disease. Memory B compartment decreased in severe and critical cases, and antibody-secreting cells are increased according to the severity of the disease. Other non-typical subsets such as double-negative B cells also showed significant changes according to disease severity. Globally, these differences allow us to identify severity-associated patient clusters with specific altered subsets. Finally, respiratory parameters, biomarkers of inflammation, and clinical scores exhibited correlations with some of these subpopulations. The severity of COVID-19 is accompanied by changes in the B cell subpopulations, either immature or terminally differentiated. Furthermore, the existing relationship of B cell subset frequencies with clinical and laboratory parameters suggest that these lymphocytes could serve as potential biomarkers and even active participants in the adaptive antiviral response mounted against SARS-CoV-2.

The formation of B cell immunological memory happens after the first encounter with a pathogen. At the germinal center (GC), B cells experience complex transcriptional and epigenetic transitions to differentiate into memory B cells (MBCs) and plasma cells (PCs). In particular, the differentiation of GC B cells into MBCs has been poorly understood, and no clear conclusions on the signals and transcription factors leading to this cell fate have been identified. Recent discoveries in epigenetics and immune memory have elucidated the essential role of epigenetic regulators in establishing the memory B cell (MBC) fate. DNA methylation regulators, histone modifiers, noncoding RNAs (ncRNAs), and chromatin remodelers orchestrate a dynamic reprograming of the MBC phenotype. Positive and negative epigenetic regulators of the B cell program collaborate at each differentiation stage and allow for complex chromatin topology rearrangements and dynamic exposure to transcription and translation. Following MBC fate determination at the GC, the acquired epigenetic modifications induce a poised regulatory state where genes are epigenetically marked to remain transcriptionally inactive, but primed for rapid activation upon stimuli. Thus, a poised epigenetic control over gene expression governs MBC formation and a novel model of epigenetic reprograming is proposed. This model provides a novel perspective on how the B cell fate is determined in the GC and memory is formed, offering insights for improved vaccination and therapeutical approaches.

Abstract Autoreactive B cell activity defines the earliest detectable stage (Stage 1) of type 1 diabetes (T1D) but is incompletely understood, particularly for B cells reactive against the key T1D autoantigen, insulin. To test whether Stage 1 T1D B cells are transcriptionally rewired compared to healthy individuals, we performed single-cell transcriptional, phenotypic, and immune repertoire profiling of CD19+ cells isolated from the peripheral blood of Stage 1 T1D individuals, identified via Type 1 Diabetes TrialNet as being positive for ≥ 2/5 islet autoantibodies, and healthy controls. Stage 1 T1D memory B cells upregulated n = 122 genes compared to healthy controls, including genes involved in actin cytoskeleton rearrangement, B cell receptor (BCR) signaling, and antigen presentation, and exhibited reduced BCR somatic hypermutation, particularly in atypical-like memory B cells. Clonally expanded B cells in the atypical-like memory subset of Stage 1 T1D individuals exhibited avidity driven insulin-binding specificities, without polyreactivity to HEp-2 cell autoantigens. Insulin-binding B cells showed non-significant upregulation of genes involved in key B cell functions. Our findings highlight transcriptional and BCR-repertoire differences in Stage 1 T1D B cells with potential for optimization as future screening tools to identify rare, autoreactive B cells and biomarkers of T1D progression.

B cells secrete antibodies and mediate the humoral immune response, making them extremely important in protective immunity against SARS-CoV-2, which caused the coronavirus disease 2019 (COVID-19) pandemic. In this review, we summarize the positive function and pathological response of B cells in SARS-CoV-2 infection and re-infection. Then, we structure the immunity responses that B cells mediated in peripheral tissues. Furthermore, we discuss the role of B cells during vaccination including the effectiveness of antibodies and memory B cells, viral evolution mechanisms, and future vaccine development. This review might help medical workers and researchers to have a better understanding of the interaction between B cells and SARS-CoV-2 and broaden their vision for future investigations.

By examining the B-cell receptor (BCR) repertoire of metastatic melanoma (MM) patients with favorable treatment outcomes, it is now possible to identify unique patterns of immune responses, with the potential of discovering novel antitumor antibodies. Here, we isolated CD27-positive circulating memory B cells from non responders, partial responders, and complete responders MM patients to first-line therapy with anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab, to perform a BCR repertoire sequencing analysis. We looked for complementarity-determining region 3 (CDR3) sequences that were enriched ( formed) following ICI treatment. Fully-human immunoglobulins were then produced in Expi293F™ cells using CDR3-sequencing information and tested for specificity and sensitivity on different MM cell lines and patient-derived xenograft cells by flow cytometry and by immunohistochemistry on human tissue microarrays. As a result of immunotherapy stimulation in responder patients, we observed that some CDR3 clonotypes have emerged . Among the nine candidate antibodies we assessed, two antibodies exhibited encouraging tumor-targeting properties, although they also showed a degree of cross-reactivity with normal skin and melanocytes. Although our study is based on a limited number of individuals, our observations indicate that it may be possible to further investigate the human response to immunotherapy for the identification of rare mature B clonotypes targeting plasma membrane antigens on tumor cells. These preliminary findings could contribute to the future development of fully human-compatible immunotherapies, pending additional validation and studies.

Epstein-Barr virus-positive large B-cell lymphoma (EBV+ LBCL) is a heterogeneous group of diseases that may resemble classic Hodgkin lymphoma (CHL) both morphologically and immunophenotypically. However, these diseases are treated with different therapies and carry distinct prognoses. We examined CD200 expression by immunohistochemistry in EBV+ LBCL and evaluated its diagnostic utility in the differential diagnosis with CHL. CD200 immunohistochemistry was performed on archival material from 20 cases of CHL (11 EBV+, 9 EBV-), 11 cases of EBV+ LBCL, and 10 cases of diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS). Staining pattern and intensity (0-3+ scale) were recorded. CD200 positivity was seen in Reed-Sternberg cells in 19 (95%) of 20 cases of CHL, predominantly in a strong (3+, 15/19) and diffuse (>50% of cells, 17/19) pattern. In contrast, CD200 was negative in 8 (73%) of 11 cases of EBV+ LBCL; the 3 positive cases showed 1 to 2+ staining in less than 50% of lesional cells. All cases of DLBCL NOS were negative for CD200. CD200 may be a useful immunophenotypic marker in differentiating EBV+ LBCL from CHL, with negative to partial/weak staining favoring a diagnosis of EBV+ LBCL and strong diffuse staining favoring a diagnosis of CHL.